Identification and structural characterization of a mutant KRAS‐G12V specific TCR restricted by HLA‐A3
Mutations in KRAS are some of the most common across multiple cancer types and are thus attractive targets for therapy. Recent studies demonstrated that mutant KRAS generates immunogenic neoantigens that are targetable by adoptive T‐cell therapy in metastatic diseases. To expand mutant KRAS‐specific...
Main Authors: | Sim, MJW, Hanada, K, Stotz, Z, Yu, Z, Lu, J, Brennan, P, Quastel, M, Gillespie, GM, Long, EO, Yang, JC, Sun, PD |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Wiley
2024
|
Similar Items
-
T cells discriminate between groups C1 and C2 HLA-C
by: Sim, MJW, et al.
Published: (2022) -
Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
by: Qi Ai, et al.
Published: (2023-05-01) -
1168 Identification of fully human TCR-mimic antibodies targeting the KRAS G12V/HLA complex generated in HLA-transgenic RenMabTM mice
by: Yi Yang, et al.
Published: (2023-11-01) -
378 Development of a clinical candidate TCR for mutant KRAS using a high-precision cell-based platform
by: Sara Horta, et al.
Published: (2023-11-01) -
Major TCR repertoire perturbation by immunodominant HLA-B*44:03-restricted CMV-specific T cells
by: Attaf, M, et al.
Published: (2018)